My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pulse Biosciences, Inc - Common Stock (NQ:PLSE)

17.52 -0.05 (-0.28%)
Streaming Delayed Price Updated: 12:10 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 38,747
Open 17.43
Bid (Size) 17.47 (2)
Ask (Size) 17.58 (1)
Prev. Close 17.57
Today's Range 17.24 - 17.87
52wk Range 13.77 - 25.00
Shares Outstanding 54,902,942
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire

Performance

YTD
-1.5%
-1.5%
1 Month
+5.3%
+5.3%
3 Month
+11.9%
+11.9%
6 Month
-1.2%
-1.2%
1 Year
+0.7%
+0.7%

More News

Read More
Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
From Pulse Biosciences
Via Business Wire
Earnings Scheduled For May 8, 2025
Via Benzinga
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences’ nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Cash Jumps in Q2
Via The Motley Fool
Topics Intellectual Property
Pulse Biosciences Inc (NASDAQ:PLSE) Reports Q2 2025 Earnings: Wider Loss, Clinical Progress in Focus
Via Chartmill
Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference
From Pulse Biosciences, Inc.
Via Business Wire
Earnings Scheduled For August 12, 2025
Via Benzinga
Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025
From Pulse Biosciences
Via Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences’ Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences’ Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
Curious about the stocks that are showing activity after the closing bell on Wednesday?
Via Chartmill

Frequently Asked Questions

Is Pulse Biosciences, Inc - Common Stock publicly traded?
Yes, Pulse Biosciences, Inc - Common Stock is publicly traded.
What exchange does Pulse Biosciences, Inc - Common Stock trade on?
Pulse Biosciences, Inc - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Pulse Biosciences, Inc - Common Stock?
The ticker symbol for Pulse Biosciences, Inc - Common Stock is PLSE on the Nasdaq Stock Market
What is the current price of Pulse Biosciences, Inc - Common Stock?
The current price of Pulse Biosciences, Inc - Common Stock is 17.52
When was Pulse Biosciences, Inc - Common Stock last traded?
The last trade of Pulse Biosciences, Inc - Common Stock was at 10/17/25 12:10 PM ET
What is the market capitalization of Pulse Biosciences, Inc - Common Stock?
The market capitalization of Pulse Biosciences, Inc - Common Stock is 961.90M
How many shares of Pulse Biosciences, Inc - Common Stock are outstanding?
Pulse Biosciences, Inc - Common Stock has 962M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.